FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4286294902> ?p ?o ?g. }

• W4286294902 endingPage "9536" @default.
• W4286294902 startingPage "9536" @default.
• W4286294902 abstract "9536 Background: The majority of patients treated with immune checkpoint inhibitors (ICIs) develop immune-related adverse events (irAE). It is currently not possible to predict the development of irAEs using biomarkers. Here we evaluated the IgG autoantibodies (AAbs) profile in pre-treatment sera of cutaneous metastatic melanoma patients treated with ICIs to identify AAbs that are associated with irAEs. Methods: Clinical data of patients with metastatic melanoma treated with pembrolizumab or nivolumab monotherapy (n = 48) or combination ipilimumab and nivolumab (n = 37) was retrospectively evaluated. irAEs were graded using CTCAE v5.0. Sera from the 85 patients were evaluated for IgG AAbs using the HuProt™ microarray v4.0 covering 23,059 proteins ( > 81% of the human proteome). AAb profiles were compared between groups (any irAEs vs no irAEs), using the no irAEs group as control group. Results were inputted into the Advaita Bio’s iPathwayGuide software to find significantly differentially expressed AAbs using p < 0.05 and Log2FC > 0.6, and identify relevant biological pathways. Results: Out of 85 patients, 60 experienced any grade irAEs, 29 of 48 (60.4%) in the PD-1 group and 31 of 37 (83.8%) in the combination group. We found 758 proteins were differentially elevated, 102 in the in the PD-1 group and 666 in the combination treatment group. A comparison of these groups identified 10 AAbs that were elevated in patients experiencing irAEs independent of ICI regimen. These targeted proteins are highly expressed in tissues that are commonly affected by irAEs. Previous studies have shown their links to autoimmune and inflammatory conditions such as dermatitis and thyroiditis. Pathway analysis shows the RIG like receptor signalling pathway, which has been associated with autoinflammatory conditions, was significantly affected in the PD-1 group (p = 0.011), but not in the combination group (p = 0.442). Other pathways involved included the NOD-like receptor, purine and D-amino acid metabolism which play a role in innate immune system and assembly of inflammasomes and maturation, pro-inflammatory cytokines and mediators that contribute to inflammatory response. Conclusions: Further analyses are being conducted to identify the correlation of irAE type and severity to specific autoantibodies which will be presented. Prospective studies are required for validation of these AAbs specificities. This approach could be used to identify patients at high risk of irAEs, for treatment monitoring to maintain an effective stimulation of the patient’s anti-cancer immune response, to determine if treatment cessation is required and prevent hospitalisation or lengthy immunosuppression to treat irAEs." @default.
• W4286294902 created "2022-07-21" @default.
• W4286294902 creator A5002640207 @default.
• W4286294902 creator A5005222604 @default.
• W4286294902 creator A5015041599 @default.
• W4286294902 creator A5018428237 @default.
• W4286294902 creator A5026805488 @default.
• W4286294902 creator A5039818487 @default.
• W4286294902 creator A5053472136 @default.
• W4286294902 creator A5070240933 @default.
• W4286294902 creator A5073719611 @default.
• W4286294902 date "2022-06-01" @default.
• W4286294902 modified "2023-10-16" @default.
• W4286294902 title "Autoantibodies as potential biomarkers of immune-related adverse events in patients with advanced cutaneous melanoma treated with immune checkpoint inhibitors." @default.
• W4286294902 doi "https://doi.org/10.1200/jco.2022.40.16_suppl.9536" @default.
• W4286294902 hasPublicationYear "2022" @default.
• W4286294902 type Work @default.
• W4286294902 citedByCount "0" @default.
• W4286294902 crossrefType "journal-article" @default.
• W4286294902 hasAuthorship W4286294902A5002640207 @default.
• W4286294902 hasAuthorship W4286294902A5005222604 @default.
• W4286294902 hasAuthorship W4286294902A5015041599 @default.
• W4286294902 hasAuthorship W4286294902A5018428237 @default.
• W4286294902 hasAuthorship W4286294902A5026805488 @default.
• W4286294902 hasAuthorship W4286294902A5039818487 @default.
• W4286294902 hasAuthorship W4286294902A5053472136 @default.
• W4286294902 hasAuthorship W4286294902A5070240933 @default.
• W4286294902 hasAuthorship W4286294902A5073719611 @default.
• W4286294902 hasConcept C126322002 @default.
• W4286294902 hasConcept C143998085 @default.
• W4286294902 hasConcept C159654299 @default.
• W4286294902 hasConcept C163764329 @default.
• W4286294902 hasConcept C185592680 @default.
• W4286294902 hasConcept C197934379 @default.
• W4286294902 hasConcept C203014093 @default.
• W4286294902 hasConcept C2777658100 @default.
• W4286294902 hasConcept C2777701055 @default.
• W4286294902 hasConcept C2780030458 @default.
• W4286294902 hasConcept C2780057760 @default.
• W4286294902 hasConcept C2780851360 @default.
• W4286294902 hasConcept C2781197716 @default.
• W4286294902 hasConcept C2781433595 @default.
• W4286294902 hasConcept C502942594 @default.
• W4286294902 hasConcept C55493867 @default.
• W4286294902 hasConcept C71924100 @default.
• W4286294902 hasConcept C8891405 @default.
• W4286294902 hasConceptScore W4286294902C126322002 @default.
• W4286294902 hasConceptScore W4286294902C143998085 @default.
• W4286294902 hasConceptScore W4286294902C159654299 @default.
• W4286294902 hasConceptScore W4286294902C163764329 @default.
• W4286294902 hasConceptScore W4286294902C185592680 @default.
• W4286294902 hasConceptScore W4286294902C197934379 @default.
• W4286294902 hasConceptScore W4286294902C203014093 @default.
• W4286294902 hasConceptScore W4286294902C2777658100 @default.
• W4286294902 hasConceptScore W4286294902C2777701055 @default.
• W4286294902 hasConceptScore W4286294902C2780030458 @default.
• W4286294902 hasConceptScore W4286294902C2780057760 @default.
• W4286294902 hasConceptScore W4286294902C2780851360 @default.
• W4286294902 hasConceptScore W4286294902C2781197716 @default.
• W4286294902 hasConceptScore W4286294902C2781433595 @default.
• W4286294902 hasConceptScore W4286294902C502942594 @default.
• W4286294902 hasConceptScore W4286294902C55493867 @default.
• W4286294902 hasConceptScore W4286294902C71924100 @default.
• W4286294902 hasConceptScore W4286294902C8891405 @default.
• W4286294902 hasIssue "16_suppl" @default.
• W4286294902 hasLocation W42862949021 @default.
• W4286294902 hasOpenAccess W4286294902 @default.
• W4286294902 hasPrimaryLocation W42862949021 @default.
• W4286294902 hasRelatedWork W2155654588 @default.
• W4286294902 hasRelatedWork W2285109017 @default.
• W4286294902 hasRelatedWork W2580215808 @default.
• W4286294902 hasRelatedWork W2607780130 @default.
• W4286294902 hasRelatedWork W2773756552 @default.
• W4286294902 hasRelatedWork W2903811712 @default.
• W4286294902 hasRelatedWork W2981883049 @default.
• W4286294902 hasRelatedWork W3029766637 @default.
• W4286294902 hasRelatedWork W3119950328 @default.
• W4286294902 hasRelatedWork W4292373623 @default.
• W4286294902 hasVolume "40" @default.
• W4286294902 isParatext "false" @default.
• W4286294902 isRetracted "false" @default.
• W4286294902 workType "article" @default.